SUBSCRIBE HomeNews & Opinion Genetic Variant Discovered in Amish Protects from Heart Disease Researchers link a missense mutation in the B4GALT1 gene to lower levels of LDL cholesterol and the blood clotting factor fibrinogen. Abby Olena Dec 2, 2021 3 ABOVE: An artist’s rendition of cholesterol blocking an artery © ISTOCK.COM, RASI BHADRAMANI A gene variant initially uncovered in the genomes of people belonging to the Old Order Amish has been linked in a new study to lower levels of fibrinogen (a blood clotting factor) and low-density lipoprotein (LDL) cholesterol—both of which, when elevated, increase a person’s risk of developing cardiovascular disease. The work, published today (December 2) in Science, not only connects a missense mutation in the enzyme-coding gene beta-1,4-galactosyltransferase 1 (B4GALT1) with heart health in humans, but confirms the link in mice. “This is a very good example of the utility of small founder or isolated populations in predicting genetic effects of genes that could not easily be identified even in the very big human biobanks that are available worldwide,” Caroline Hayward, who studies human genetics at the University of Edinburgh and did not participate in the study, writes in an email to The Scientist. May Montasser, a genetic epidemiologist at the University of Maryland School of Medicine, and colleagues study the genomes of the Old Order Amish because approximately 35,000 people alive today can trace their family history back to a small number of founder families. Due to the small pool of genetic starting material, this population harbors less genetic diversity than the general population, meaning that variants that might disappear in larger groups can be maintained in Old Order Amish populations and therefore be easier to spot. See “Human Mutation Rates Steady Across Groups—Except in the Amish” In the new study, Montasser and colleagues sequenced the exons of 6,890 Old Order Amish subjects and found a missense mutation in B4GALT1, which is expressed throughout the body and encodes an enzyme that transfers galactose to proteins. The variant was associated with lower LDL cholesterol and was present in six percent of the Amish genomes but is much rarer outside the Amish community. The researchers found it in only eight of 140,000 non-Amish genomes that are part of a National Heart, Lung, and Blood Institute database. When the team looked at other factors related to cardiovascular health in people carrying the missense mutation, they found no association with triglycerides and a small association with high density lipoprotein cholesterol. The blood clotting factor fibrinogen, which can be a risk factor for cardiovascular disease when elevated, was lower in people with the variant. To assess whether the missense mutation in B4GALT was linked with overall cardiovascular health, the researchers shifted their focus outside the relatively healthy Amish population to the Geisinger Health System and the UK Biobank, two larger genomic databases. Because the specific variant they identified in the Amish is so rare in the general population, Montasser and her colleagues pulled out genomes with any variant of B4GALT. These individuals had decreased LDL, fibrinogen, and a 35 percent reduction in cardiovascular disease. When the researchers generated knock-in mice with the B4GALT variant, the animals also had lower LDL and fibrinogen. Knocking the gene down just in the rodents’ livers led to lower levels of circulating LDL. The authors explain in the paper that this finding could point to the usefulness of targeting B4GALT expression in the liver therapeutically to lower LDL cholesterol. “The study provides strong evidence that this newly discovered mutation is relevant across population and species,” Kari North, a genetic epidemiologist at the University of North Carolina at Chapel Hill who did not participate in the work, writes in an email to The Scientist. B4GALT “may represent a new drug target for decreasing LDL-cholesterol and downstream [cardiovascular disease]. However, years of work are still needed to develop this new discovery into a new pharmaceutical target,” she adds. Before getting to the point of clinical relevance, “we have to make sure that there are not any harmful side effects [associated with] having this variant,” Montasser explains. “Having low LDL is great; having low fibrinogen is great, but is there anything else harmful? So far, based on all the other information we have, everything looks good. Those people look perfectly healthy, but we are doing even more deep phenotyping right now to make sure that we are not missing anything.” Another issue is that “it’s not clear how we go from having this variant to having low LDL and low fibrinogen and protection from cardiovascular disease,” she says. The research team is trying to characterize that mechanism in animal models and human samples now. Montasser says they will “keep working on it [and] hopefully someday we’ll have some form of therapy based on this.” Keywords: Amishblood clotcholesterolgeneticsgenomicsheartheart diseasehumanmouse modelNewspopulation geneticspublic health Related Articles Opinion: The Pandemic and the RNA Sequencing Gap Noncoding RNA Improves Symptoms in Mice with Metabolic Disorder First US Field Test of GM Mosquitoes Begins in Florida Australian Lab Cultures New Coronavirus as Infections Climb Related Research Resources Technique Talk: CRISPR for Genome Engineering in Drosophila Webinars The Scientist Speaks - Molecular Farming: The Future of Pharmaceuticals Podcasts Biomarkers on the Brain: From Sequencing to Functional Imaging Webinars The Scientist Speaks - Ancient Secrets of the Plague Podcasts Trending Moderna vs. Pfizer: Is There a “Best” mRNA Vaccine? Omicron Is WHO’s Fifth Variant of Concern, Experts Urge Patience 2021 Top 10 Innovations Over the Counter Antihistamines Could Help Against Cancer Multimedia December 2021 Interactive Crossword Infographic: How Worms that Reside in the Gut Could Influence Health DECEMBER 2021 Return of the worms Researchers are carefully considering the therapeutic potential of helminths SUBSCRIBE TODAY Return of the Worms Immunologists and parasitologists are working to revive the idea that helminths, and more specifically the molecules they secrete, could help treat allergies and autoimmune disease. 2021 Top 10 Innovations The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges. Sponsored ContentLabQuizzesWebinarsVideosInfographicseBooks Sponsored Interactive Crossword Puzzle Focus on Structure to Verify Protein Function Scientists analyze a therapeutic protein’s secondary structure to confirm drug efficacy and safety. Technique Talk: CRISPR for Genome Engineering in Drosophila Discover how CRISPR is revolutionizing gene editing in a classic genetics research model. A Library at Your Fingertips Scientists explore big questions and expand their knowledge with digital books. MarketplaceSponsored Product Updates An Early Start: The Impact of the Microbiome on Pediatric Development in the First Year of Life A better understanding of early childhood microbiome shifts offers a unique window for detecting disease risk and intervening appropriately. Dr. Aletta Schnitzler Joins TurtleTree as Chief Scientific Officer Cell-based nutrition company TurtleTree welcomes Dr. Aletta Schnitzler as its new Chief Scientific Officer (CSO). With her world-class expertise in cellular bioprocessing, Dr. Schnitzler’s appointment marks a significant stride in TurtleTree’s journey towards sustainable and efficient cellular food production. Streamlining Quality Control for Cultured Human Cells Guidelines for maintaining human cells grown ex vivo Understanding Cytokine Release Syndrome in COVID-19 Patients Researchers detect aberrant cytokine activity in response to SARS-CoV-2 infection. Stay Connected with E-NEWSLETTER SIGN-UP Subscribe to receive The Scientist Daily E-Newsletter in your inbox! Country* Please Select United States Canada United Kingdom Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua & Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia & Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Cook Islands Costa Rica Croatia Cuba Curacao Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Gaza Strip Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard & McDonald Islands Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Northern Mariana Islands Norfolk Island North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Republic of the Congo Reunion Romania Russia Rwanda Saint Helena Saint Barthelemy Saint Kitts & Nevis Saint Lucia Saint Martin Saint Pierre & Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome & Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia & South Sandwich Islands South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad & Tobago Tunisia Turkey Turkmenistan Turks & Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates Uruguay US Minor Outlying Islands US Virgin Islands Uzbekistan Vanuatu Vatican City State Venezuela Vietnam Wallis and Futuna West Bank Western Sahara Yemen Zambia Zimbabwe FACEBOOK PAGES THE SCIENTISTCANCER AND GENOMIC SCIENCECELL AND MICROBIAL SCIENCETHE NEUROSCIENTISTTHE SCIENTIST CAREERS ABOUT & CONTACTEDITORIAL ADVISORY BOARDEDITORIAL POLICIESPRIVACY POLICY JOB LISTINGSSUBSCRIBEADVERTISE NOW PART OF THE LABX MEDIA GROUP:LAB MANAGER MAGAZINE|LABX|LABWRENCH © 1986–2021 THE SCIENTIST. ALL RIGHTS RESERVED. We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience. I UNDERSTAND